Provided by Tiger Trade Technology Pte. Ltd.

Compass Therapeutics, Inc.

0.9749
-0.0451-4.42%
Volume:3.86M
Turnover:3.78M
Market Cap:175.57M
PE:-2.41
High:1.01
Open:1.01
Low:0.9573
Close:1.02
52wk High:6.88
52wk Low:0.8294
Shares:180.09M
Float Shares:132.00M
Volume Ratio:0.41
T/O Rate:2.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4039
EPS(LYR):-0.4216
ROE:-56.66%
ROA:-33.03%
PB:1.06
PE(LYR):-2.31

Loading ...

Compass Therapeutics price target lowered to $6 from $12 at Stifel

TIPRANKS
·
Apr 28

Compass Therapeutics selloff ‘an over-reaction,’ says Jefferies

TIPRANKS
·
Apr 28

Leerink says Compass data supports path forward for tovecimig in 2L BTC

TIPRANKS
·
Apr 28

This Biotech Stock Is Down 61%. How a Cancer Trial Was Ruined by Its Own Design. -- Barrons.com

Dow Jones
·
Apr 28

LifeSci Capital Sticks to Its Buy Rating for Compass Therapeutics (CMPX)

TIPRANKS
·
Apr 27

Wedbush Lowers Compass Therapeutics Price Target to $5 From $8, Maintains Outperform Rating

MT Newswires Live
·
Apr 27

Compass Therapeutics Shares Down 63% at $1.84 After Cancer Drug Fails Overall Survival Trial Goal

THOMSON REUTERS
·
Apr 27

Compass Therapeutics Inc. Shares Down 72.2% at $1.40 in Premarket Trade After Trial Results for Tovecimig

THOMSON REUTERS
·
Apr 27

Compass Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Apr 27

BRIEF-Compass Therapeutics Inc. Tovecimig Plus Paclitaxel Improves Median Pfs To 4.7 Months Versus 2.6 Months

Reuters
·
Apr 27

Top Premarket Decliners

MT Newswires Live
·
Apr 27

Compass Therapeutics Bile Cancer Treatment Doesn't Meet Overall Survival Goal

Dow Jones
·
Apr 27

Compass says tovecimig plus paclitaxel extends PFS in biliary tract cancer trial

Reuters
·
Apr 27

Compass Therapeutics Inc. - Tovecimig Plus Paclitaxel Improves Median Pfs to 4.7 Months VS 2.6 Months

THOMSON REUTERS
·
Apr 27

Tovecimig Demonstrates Statistically Significant Benefit in Companion-002 Randomized Phase 2/3 Study in Patients With Biliary Tract Cancer

THOMSON REUTERS
·
Apr 27

Compass Therapeutics Inc.: Met Key Secondary Endpoint of Pfs and Showed Additional Compelling Results in Randomized Companion-002 Study

THOMSON REUTERS
·
Apr 27

NASDAQ TRADE HALT HALT NEWS PENDING AT 07:25 AM

Reuters
·
Apr 27

Compass Therapeutics Shares Gain Ahead of Trial Data for Biliary Tract Cancer Drug

Dow Jones
·
Apr 25

Compass Therapeutics to report COMPANION-002 secondary endpoints for tovecimig in biliary cancer

Reuters
·
Apr 25

Compass Therapeutics (CMPX): Favorable Risk‑Reward Ahead of Pivotal Tovecimig Data in Biliary Tract Cancer

TIPRANKS
·
Apr 07